Evidence map›Paper›PMID 38079104›Full record

SynthesisDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2024

Effectiveness of epigallocatechin gallate nanoparticles on the in-vivo treatment of Alzheimer's disease in a rat/mouse model: a systematic review.

Maha K A Khalifa, Somaia A Abdel-Sattar, Omnya M Amin, Neveen A Kohaf, Heba S Zaky, Marwa A Abd El-Fattah, Kamilia H A Mohammed, Noha M Badawi, Ihab Mansoor, Heba A Eassa

Open access · greenAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Maha K A KhalifaDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, 11884, Egypt.ORCID http://orcid.org/0000-0002-8053-8059
Somaia A Abdel-SattarDepartment of Pharmacology and Toxicology, Faculty of Pharmacy (Girls), Al-Azhar University, 11884, Cairo, Egypt.ORCID http://orcid.org/0000-0002-7715-6156
Omnya M AminDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, 11884, Egypt.
Neveen A KohafDepartment of Clinical Pharmacy, Faculty of Pharmacy, Al-Azhar University, Cairo, 11884, Egypt.ORCID http://orcid.org/0000-0002-0369-6176
Heba S ZakyDepartment of Pharmacology and Toxicology, Faculty of Pharmacy (Girls), Al-Azhar University, 11884, Cairo, Egypt.ORCID http://orcid.org/0000-0001-6502-516X
Marwa A Abd El-FattahDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, 11884, Egypt.ORCID http://orcid.org/0000-0002-5275-0810
Kamilia H A MohammedDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, 11884, Egypt.ORCID http://orcid.org/0000-0003-0427-639X
Noha M BadawiDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt.ORCID http://orcid.org/0000-0002-3823-5804
Ihab MansoorNarrativa, Los Angeles, CA, 90028, USA.ORCID http://orcid.org/0000-0001-7046-8184
Heba A EassaDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, 11884, Egypt. heassa@usj.edu.ORCID http://orcid.org/0000-0001-8888-3749
Al-Azhar University · EGBritish University in Egypt · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) is a neurological disease that causes memory loss over time. Current therapies are limited and frequently inadequate. Epigallocatechin gallate (EGCG), has antioxidant, anti-inflammatory, antifibrosis, anti-remodeling and tissue-protective qualities that may be effective in treatment of different diseases, including AD. Because of nanoparticles' high surface area, they can enhance solubility, stability, pharmacokinetics and biodistribution, and diminish toxicities. Besides, lipid nanoparticles have a high binding affinity that can enhance the rate of drug transport across BBB. So, EGCG nanoparticles represent a promising treatment for AD.

objectivesThis systematic review sought to assess the efficacy of EGCG nanoparticles against AD in rat/mouse models.

methodsStudy was conducted in accordance with PRISMA guidelines, and the protocol was registered in PROSPERO. Electronic databases were searched to discover relevant studies published up to October 2022.

resultsTwo studies met the inclusion criteria out of 1338 and were included in this systematic review. Collectively, the results indicate that EGCG has a significant potential for reducing AD pathology and improving cognitive deficits in rat/mouse models. The formulated particles were in the nanometer range, as indicated by TEM, with good particle size control and stability. EGCG nanoparticles showed superior pharmacokinetic characteristics and improved blood-brain barrier permeability, and increased brain bioavailability compared to free EGCG. Additionally, nanoEGCG were more effective in modulating oxidative stress than free formulation and decreased AChE in the cortex and hippocampus of AlCl3-treated rats.

conclusionThis systematic analysis of the two studies included showed that EGCG nanoparticles are efficacious as a potential therapeutic intervention for AD in rat/mouse models. However, limited number of studies found indicates insufficient data in this research point that requires further investigation by experimental studies.

Indexed as

Alzheimer DiseaseCatechinDisease Models, AnimalNanoparticlesAnimalsAntioxidantsMiceNeuroprotective AgentsRatsAntioxidantsCatechinepigallocatechin gallateNeuroprotective AgentsAlzheimer'sEpigallocatechin gallateIn vivoNanoparticles

Identifiers

PMID38079104
PMCPMC11087435
OpenAlexW4389540730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.